Quarterly ResultMay 14, 2026, 04:09 PM
Serina Therapeutics Reports Q1 Net Loss $(6.9)M; Raises $26.0M in Financing
AI Summary
Serina Therapeutics reported a net loss of $6.9 million for Q1 2026, an increase from $4.8 million in Q1 2025, with a basic and diluted net loss per common share of $(0.58). Despite increased operating expenses, the company significantly boosted its cash and cash equivalents to $24.5 million and moved from a stockholders' deficit to $17.6 million in equity, primarily through $26.0 million in financing activities. These activities included a March 2026 PIPE and at-the-market sales. However, management expressed substantial doubt about the company's ability to continue as a going concern, as current capital is not expected to cover anticipated operating needs for the next 12 months.
Key Highlights
- Net loss for Q1 2026 was $(6.9) million, up from $(4.8) million in Q1 2025.
- Basic and diluted net loss per share was $(0.58) in Q1 2026, compared to $(0.49) in Q1 2025.
- Cash and cash equivalents increased to $24.5 million as of March 31, 2026, from $3.1 million.
- Total stockholders' equity improved to $17.6 million from a $(37) thousand deficit.
- Net cash provided by financing activities was $26.1 million in Q1 2026.
- Proceeds from March 2026 PIPE totaled $15.9 million, net of costs.
- Proceeds from at-the-market sales agreement were $10.2 million, net.
- Management expressed substantial doubt about the company's ability to continue as a going concern.